Varicose Vein — Cost, Top Hospitals & Success Rates | MyMedicPlus

Varicose veins are enlarged, twisted, rope-like veins that bulge beneath the surface of the skin, most commonly appearing in the legs and feet. They develop when the one-way valves inside superficial veins weaken or fail, allowing blood to pool and cause the vein wall to stretch and distort. Affecting approximately 23–29% of adults globally, varicose veins range from a cosmetic nuisance to a source of significant pain, skin changes, and — if untreated — chronic venous insufficiency with potential complications such as venous ulcers or deep vein thrombosis.

The venous system of the lower limb is divided into superficial and deep systems connected by perforator veins. The great saphenous vein (GSV) is the most frequently affected vessel; incompetence at the saphenofemoral junction (SFJ) is responsible for the majority of primary varicose veins. The small saphenous vein (SSV), connecting the popliteal fossa to the ankle, is the second most common site of incompetence.

Modern treatment has shifted decisively away from traditional open surgical stripping toward minimally invasive, catheter-based, or injection-based techniques performed under local anaesthesia as day-case procedures. The goals of treatment are symptom relief, prevention of disease progression, improved cosmetic appearance, and healing or prevention of skin complications such as lipodermatosclerosis and venous ulcers.

This guide covers all evidence-based treatment pathways endorsed by major vascular societies including NICE (UK), the Society for Vascular Surgery (SVS), the American Venous Forum (AVF), and the European Society for Vascular Surgery (ESVS).

Varicose vein interventions address a spectrum of venous disease classified by the internationally recognised CEAP (Clinical-Etiology-Anatomy-Pathophysiology) system:

• C1 — Telangiectasias and reticular veins: Spider veins (<1 mm) and bluish reticular veins (1–3 mm) that are primarily cosmetic but may cause mild burning or itching.
• C2 — Varicose veins: Dilated, tortuous veins >3 mm in diameter when measured standing. The hallmark presentation that most patients seek treatment for.
• C3 — Oedema: Chronic venous oedema of the lower leg, ankle pitting, and a feeling of heaviness, particularly worse after prolonged standing.
• C4a — Pigmentation and eczema: Haemosiderin deposition causes brownish skin discolouration (hyperpigmentation). Venous eczema (stasis dermatitis) presents as red, itchy, weeping skin.
• C4b — Lipodermatosclerosis and atrophie blanche: Fibrotic hardening of subcutaneous tissue with scarring, indicating advanced chronic venous insufficiency (CVI).
• C5 — Healed venous ulcer: Evidence of a previously healed ulcer, indicating high risk of recurrence without definitive treatment.
• C6 — Active venous ulcer: Open ulceration, typically near the medial malleolus, requiring urgent intervention. Venous ulcers account for 70–80% of all chronic leg ulcers.

Associated conditions that drive treatment decisions include superficial venous thrombophlebitis (painful, inflamed clot in a varicose segment), bleeding from a superficial varix, and recurrent varicose veins following previous surgery. Pelvic congestion syndrome causing vulvar and perineal varices is a related condition requiring dedicated imaging and treatment.

Candidacy for varicose vein treatment is determined through clinical assessment combined with duplex ultrasound (DUS) mapping — the cornerstone diagnostic investigation that identifies reflux, source of incompetence, and vein diameter. Treatment is generally indicated for symptomatic varicose veins (C2–C6) or documented haemodynamic reflux causing functional limitation.

Suitable candidates include:

• Adults with symptomatic varicose veins causing aching, heaviness, throbbing, cramps, pruritus, or restless legs that interfere with daily activity.
• Patients with skin changes (C4–C6) or active/healed venous ulcers where ablating the source of reflux accelerates healing and prevents recurrence.
• Individuals with GSV or SSV incompetence confirmed on duplex scanning with axial reflux >0.5 seconds.
• Patients who have failed or are intolerant of conservative measures (compression stockings, leg elevation, lifestyle modification) for 3–6 months.
• Those with cosmetically troubling varicosities significantly affecting quality of life even without pain.

Relative contraindications and special considerations:

• Pregnancy: Treatment is generally deferred until 3–6 months postpartum; compression stockings are first-line during pregnancy.
• Morbid obesity: Increases anaesthetic risk and reduces technical success; weight optimisation may be advised pre-procedure.
• Peripheral arterial disease: ABPI <0.8 is a caution for compression therapy; arterial status must be assessed before any venous intervention.
• Deep vein thrombosis or post-thrombotic syndrome: DUS required to exclude deep venous obstruction before superficial ablation, as varicosities may be functioning as collaterals.
• Immobility or inability to mobilise post-procedure: Increases DVT risk; ambulatory status should be confirmed.
• Coagulopathy or anticoagulant therapy: Requires management in coordination with the treating haematologist.

Contemporary varicose vein management offers a range of modalities matched to vein size, anatomy, and patient factors:

1. Endovenous Laser Ablation (EVLA / EVLT)

The most widely adopted first-line treatment for truncal varicose veins (GSV, SSV). A laser fibre is inserted into the incompetent vein under duplex guidance. Laser energy (typically 1,470 nm wavelength) heats the vein wall, causing immediate closure. Performed under tumescent local anaesthesia. Success rates exceed 95% at 5 years. The procedure typically takes 45–60 minutes and patients walk out and return to normal activities within 1–2 days.

2. Radiofrequency Ablation (RFA)

Uses radiofrequency energy delivered through a segmented catheter (ClosureFAST system) to heat and close the vein. Comparable efficacy to EVLA (94–96% closure at 5 years) with slightly lower post-procedural bruising and pain in some trials. Also performed under tumescent local anaesthesia as a day case.

3. Ultrasound-Guided Foam Sclerotherapy (UGFS)

A sclerosant agent (polidocanol or sodium tetradecyl sulphate) is mixed with CO₂ to create foam, then injected under duplex guidance into the incompetent vein. The foam displaces blood and causes endothelial damage leading to fibrosis and obliteration. Lower capital cost than thermal ablation; suitable for recurrent varicosities, incompetent perforators, and smaller accessory veins. Slightly lower long-term closure rates than thermal ablation (70–80% at 5 years) with higher retreatment rates.

4. Mechanochemical Ablation (MOCA — ClariVein)

Combines mechanical wire rotation with simultaneous sclerosant infusion to damage the endothelium and achieve closure without tumescent anaesthesia or thermal energy. Avoids the risk of nerve injury from heat. Success rates of ~80–90% at 2–3 years. Particularly useful where tumescent injection is technically difficult.

5. Cyanoacrylate Glue (VenaSeal)

A medical-grade cyanoacrylate adhesive is injected into the vein under ultrasound guidance, bonding the vein walls without thermal energy or sclerosant. No tumescent anaesthesia required. Good short-term closure rates (~95% at 1 year) but longer-term comparative data still maturing. Higher material cost but excellent patient tolerance.

6. Ambulatory Phlebectomy (Avulsions)

Varicose tributaries are removed through tiny stab incisions (2–3 mm) under local anaesthesia as a day case. Often performed as an adjunct to truncal ablation for the same session or as a second-stage procedure. Excellent cosmetic outcomes with minimal scarring.

7. Conventional Surgery (High Ligation and Stripping)

Formerly the gold standard, now largely replaced by minimally invasive techniques. SFJ flush ligation through a groin incision combined with GSV stripping remains appropriate for very large incompetent veins, recurrence requiring open exploration, or anatomically complex cases. Performed under general or spinal anaesthesia; recovery 1–2 weeks.

8. Compression Sclerotherapy

Liquid or foam sclerosant injected into telangiectasias and reticular veins without ultrasound guidance, followed by compression. The standard treatment for cosmetic spider veins and small reticular veins not suitable for thermal ablation. Multiple sessions typically required.

Effective varicose vein treatment delivers substantial clinical and quality-of-life improvements backed by high-quality randomised controlled evidence:

• Symptom relief: The majority of patients report significant reduction in leg aching, heaviness, swelling, night cramps, and restless legs within weeks of treatment. Patient-reported outcome scores (AVVQ, CIVIQ) improve markedly and durably.
• High technical success: Modern endovenous techniques achieve truncal vein closure in 90–98% of cases at 1 year, with durable results at 5 years comparable to or exceeding surgical stripping.
• Cosmetic improvement: Removal of bulging tributaries by phlebectomy or injection produces excellent cosmetic results, enhancing self-confidence and reducing social anxiety related to vein appearance.
• Prevention of disease progression: Eliminating the source of venous hypertension slows or stops progression from C2 toward advanced CEAP classes (C4–C6).
• Venous ulcer healing: The EVRA trial (2018, NEJM) demonstrated that early endovenous ablation alongside compression therapy healed venous ulcers faster (mean 56 vs 82 days) and with higher 24-week healing rates (85% vs 53%) compared to compression alone.
• Minimally invasive advantages: Day-case procedures with local anaesthesia, immediate ambulation, return to work within 1–2 days (compared to 1–2 weeks for surgery), minimal scarring, and lower complication rates compared to open surgery.
• Low recurrence with proper technique: Meticulous DUS-guided treatment targeting all reflux sources reduces recurrence significantly over the medium term.
• Cost-effectiveness: NICE health technology assessments confirm endovenous thermal ablation is cost-effective compared to open surgery when day-case savings and faster recovery are factored in.

Varicose vein treatments are generally very safe, but patients should be informed of the following risks stratified by frequency and severity:

Common (1–15% of patients):

• Bruising and haematoma: Expected after phlebectomy and thermal ablation; typically resolves within 2–4 weeks.
• Thrombophlebitis: Inflammatory reaction in treated or adjacent veins, causing transient pain, redness, and induration. Usually self-limiting with NSAIDs and ambulation.
• Hyperpigmentation: Brown skin staining from haemosiderin, particularly after sclerotherapy. Usually fades over 6–12 months; rarely permanent.
• Matting: Fine new telangiectasias around injection or ablation sites, particularly after sclerotherapy. May require further treatment.

Uncommon (0.1–1%):

• Endothermal Heat-Induced Thrombosis (EHIT): Extension of thrombus into the deep venous system at the SFJ following thermal ablation. Managed with anticoagulation; rarely causes clinically significant DVT if managed promptly with surveillance DUS.
• Deep vein thrombosis (DVT) and pulmonary embolism (PE): Risk of DVT after varicose vein treatment is approximately 0.5–1% — lower than for open surgery. Early ambulation and appropriate thromboprophylaxis are protective.
• Nerve injury: Saphenous nerve (medial calf) or sural nerve (lateral ankle) paraesthesia after thermal ablation. Risk reduced by tumescent anaesthesia, which creates a protective fluid buffer. Usually transient; permanent deficit is rare (<1%).
• Skin burns: From laser or RF energy in superficial veins; mitigated by tumescent technique.

Rare (<0.1%):

• Anaphylaxis: Rare allergic reaction to sclerosant agents.
• Visual disturbances and neurological events: Rare after foam sclerotherapy, particularly in patients with a patent foramen ovale (PFO) through which microbubbles may paradoxically embolise. CO₂-based foam reduces this risk; PFO screening is advised in high-volume foam injections.
• Serious infection or sepsis: Extremely rare with proper aseptic technique.

Patients are generally discharged with a compression stocking prescription and advised to walk 30 minutes daily. Follow-up duplex scanning at 3–7 days and again at 3–6 months ensures adequate closure and detects EHIT early.

Post-procedure management is integral to optimising outcomes after varicose vein treatment:

Immediate post-procedure (day 1–7): Patients are encouraged to walk immediately after the procedure — 30 minutes of continuous walking on the day of treatment is standard. Graduated compression stockings (class 2, 23–32 mmHg) should be worn continuously for 7 days, then during waking hours for 2–6 weeks depending on the extent of treatment. Over-the-counter analgesics (ibuprofen, paracetamol) manage procedural discomfort. Heavy lifting, vigorous exercise, prolonged standing, and hot baths should be avoided for 1–2 weeks.

Duplex ultrasound surveillance: A follow-up DUS scan is performed at 3–7 days post-thermal ablation to confirm truncal vein closure and exclude EHIT. A further scan at 3–6 months assesses durability of occlusion and identifies any residual incompetence requiring further treatment. After open surgery, DUS at 6 weeks and annually for 2 years is recommended.

Management of residual or recurrent veins: Secondary varicosities not treated in the primary session are reviewed at 6–12 weeks, when post-procedural swelling has resolved, and may be addressed by avulsion phlebectomy or foam sclerotherapy if persistent.

Long-term lifestyle recommendations: Regular aerobic exercise (particularly walking and swimming), weight management, elevation of the legs when resting, and avoidance of prolonged static standing or sitting reduce recurrence risk. Support stockings during prolonged flights or standing work protect against new varicosity development.

Venous ulcer patients (C5/C6): Require specialist wound care alongside venous treatment, with healed ulcer maintenance compression (class 3, 34–46 mmHg or elastic multilayer bandaging) and monitoring for recurrence long-term. Referral to a specialist venous ulcer clinic is recommended.

Annual review: Patients with advanced CVI (C4–C6) benefit from annual clinical review with DUS to detect new reflux segments early and manage skin complications proactively.

The cost of varicose vein treatment varies substantially depending on the modality, number of veins treated, healthcare system, and geography:

Key cost determinants:

• Treatment modality: Foam sclerotherapy is the least expensive (~USD 300–800 per session). Endovenous laser or RF ablation costs USD 1,500–5,000 per leg. Cyanoacrylate glue is premium-priced (USD 2,000–6,000) due to device costs. Open surgery including anaesthesia and hospital stay may cost USD 3,000–8,000 in private settings.
• Number of veins and extent of disease: Bilateral treatment, multiple incompetent truncal veins, or extensive tributary varicosities significantly increase cost and session count.
• Diagnostic imaging: Duplex ultrasound mapping (USD 200–600) is required pre-procedure and for follow-up.
• Anaesthesia and facility fees: Day-surgery centre charges versus hospital inpatient facilities vary widely.

Indicative regional pricing (self-pay, per leg, EVLA or RFA):

• United States: USD 2,500–6,000
• United Kingdom (private): GBP 1,500–3,500 (NHS treatment available for C3–C6 with symptomatic criteria met)
• India: USD 500–1,500
• Thailand: USD 800–2,000
• Turkey: USD 600–1,500
• Germany: EUR 1,800–4,000

Insurance coverage: Most insurers cover treatment for symptomatic varicose veins (C2–C6) confirmed by DUS; cosmetic treatment of telangiectasias is generally excluded. Pre-authorisation documentation demonstrating symptom burden, conservative treatment failure, and duplex imaging findings is typically required. Medicare and NHS criteria vary; patients should confirm coverage with their insurer prior to scheduling.

Not all patients with varicose veins require intervention. Conservative and non-interventional strategies can provide meaningful symptom control and serve as initial management or long-term maintenance:

Compression therapy: Graduated elastic compression stockings (GCS) with at least 23–32 mmHg (class 2) at the ankle are the cornerstone of conservative management. They reduce venous hypertension, alleviate symptoms (aching, swelling, heaviness), and slow disease progression. Multiple systematic reviews confirm symptomatic benefit, though stockings must be worn consistently and correctly fitted. Compression bandaging is the primary treatment for active venous ulcers.

Lifestyle modification: Regular aerobic exercise — particularly walking, cycling, and swimming — activates the calf muscle pump and improves venous return. Weight loss reduces intra-abdominal pressure and venous hypertension. Leg elevation above heart level for 30 minutes three to four times daily reduces oedema. Avoidance of prolonged standing or sitting without movement is recommended.

Pharmacotherapy (venoactive drugs): Diosmin/hesperidin (micronised purified flavonoid fraction, MPFF) and other venotonics have modest but consistent evidence for reducing symptoms of CVI (heaviness, aching, oedema) in randomised controlled trials. They are commonly used in Europe, Asia, and Latin America. Pentoxifylline is used as adjunctive therapy for venous ulcer healing alongside compression.

Newer non-thermal alternatives under evaluation: Steam vein sclerosis (SVS) uses water vapour delivered endoluminally to ablate vein walls without tumescent anaesthesia. Polidocanol endovenous microfoam (Varithena, FDA-approved) offers a standardised, nitrogen-free foam with controlled bubble size. Long-term outcome data from ongoing trials will determine their place in the evidence hierarchy.

Watchful waiting: For asymptomatic C1–C2 disease with no skin changes and minimal patient concern, observation with regular review and reassurance is an entirely appropriate strategy. Approximately 30% of varicose veins remain stable over 5 years without progression.